Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...

Some people who took a new schizophrenia drug for one year improved with only a few side effects, but many dropped out of the ...

Bristol Myers Squibb (NYSE:BMY) said its newly approved schizophrenia therapy, Cobenfy, improved disease symptoms with a well ...

26, when the U.S. Food and Drug Administration (FDA) approved Cobenfy for the psychiatric disorder. Developed by Karuna Therapeutics, which was subsequently acquired by Bristol Myers Squibb, the drug ...

Squibb “announced new topline results from the Phase 3 EMERGENT-4 and EMERGENT-5 open-label trials evaluating the ...

These are independent reviews of the products mentioned, but TIME receives a commission when purchases are made through ...

Bristol Myers Squibb Q3 revenue rose 8% YoY to $11.89 billion, driven by strong Growth Portfolio sales, especially Eliquis.

After the recent FDA approval for the promising schizophrenia drug Cobenfy (xanomeline and trospium chloride), Bristol Myers ...

The long-term trials indicated that COBENFY maintained its efficacy in reducing schizophrenia symptoms such as hallucinations, delusions, and social withdrawal. The EMERGENT-4 trial, an open-label ...

Bristol Myers Squibb to Present New Clinical and Health Economics and Outcomes Research Data at Psych Congress 2024 ...

Some people who took a new schizophrenia drug for a year improved with only a few side effects, but many dropped out of the research, the company announced Thursday. The results underscore the ...

PRINCETON, N.J. - Bristol Myers Squibb (NYSE: BMY) has released new data from its Phase 3 EMERGENT-4 and EMERGENT-5 trials, demonstrating sustained improvements in schizophrenia symptoms over a ...